We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vaso Stock Declines Post Q4 Earnings Despite Revenue Growth
Read MoreHide Full Article
Shares of Vaso Corporation (VASO - Free Report) have lost 0.1% since the company reported its earnings for the quarter ended Dec. 31, 2025, underperforming the S&P 500 Index, which gained 3.9% over the same period. Over the past month, the stock lost 6.3% compared with a 3.5% dip in the broader index.
VASO’s Earnings Snapshot
For the fourth quarter of 2025, Vaso reported revenues of $27.02 million, essentially flat compared with $27.04 million in the year-ago quarter. Gross profit increased 2.3% year over year to $17.6 million from $17.2 million, reflecting improved margins. However, quarterly net income declined 47.4% to $1.1 million from $2.1 million in the prior-year period, primarily due to higher selling, general and administrative (SG&A) expenses and a goodwill impairment charge.
On a full-year basis, revenue rose 2.7% to $89.1 million from $86.8 million, while net income increased 64.9% to $1.6 million from $0.9 million in 2024.
Segmentally, IT revenue declined 7.9% in the quarter to $10.2 million due to the divestiture of the healthcare IT unit, while professional sales service revenue grew 6.3% to $15.9 million, driven by higher equipment deliveries and commission rates. Equipment segment revenue fell 7.6% to $851 thousand due to weaker China sales.
Vaso’s Segment Performance and Margins
The professional sales service segment remained the primary growth driver, benefiting from increased equipment deliveries and higher blended commission rates. For the full year, segment revenue rose 6.9% to $44.2 million from $41.3 million, contributing significantly to overall top-line expansion. In contrast, the IT segment saw a modest decline of 1.1% annually to $42.5 million from $42.9 million, reflecting the impact of the November 2025 divestiture of the healthcare IT business. The equipment segment continued to lag, with revenue down 1.5% for the year due to lower volumes in China, partially offset by growth in U.S.-based SaaS offerings.
Gross margin improvement supported profitability, with full-year gross profit increasing 5% to $54.7 million from $52.1 million. However, operating performance was pressured by higher costs, as SG&A expenses rose 6.6% to $52.2 million from $48.9 million, driven mainly by increased personnel and travel expenses in the sales segment.
Vaso Corporation Price, Consensus and EPS Surprise
Vaso generated a strong operating cash flow of $9.3 million in 2025, up from $3.3 million in 2024, supported by higher order bookings and favorable timing of receivables. The company ended the year with $35.1 million in cash and cash equivalents, up from $26.3 million a year earlier, highlighting a solid liquidity position. Deferred revenue increased 10.6% to $38.6 million from $34.9 million, reflecting strong order activity in the professional sales service segment and providing visibility into future revenue recognition.
Vaso’s Management Commentary and Key Drivers
Management highlighted record annual revenue and emphasized sustained top-line growth alongside profitability improvements. The increase in net income for the year was attributed to higher gross profit, tax benefits and a gain on the sale of the healthcare IT business unit, partially offset by goodwill impairment and rising operating costs. VASO also noted ongoing efforts to realign its business portfolio to enhance efficiency and profitability.
Despite these positives, adjusted EBITDA turned negative $1.5 million in 2025 against a positive $1 million in 2024, indicating underlying pressure on operating earnings. The deterioration was largely linked to lower operating income and increased expenses.
Factors Influencing VASO’s Performance
Several factors shaped Vaso’s results during the period. The divestiture of the healthcare IT business reduced IT segment revenue but also contributed to gains and tax benefits. Meanwhile, higher SG&A expenses — particularly in sales and IT operations — offset gains from improved gross margins. Additionally, a goodwill impairment charge in the IT segment weighed on quarterly profitability.
Growth in the professional sales service segment was supported by strong demand for GE HealthCare equipment and improved commission structures, underscoring the importance of this segment to VASO’s overall performance.
Vaso’s Other Developments
A key development during the quarter was the sale of Vaso’s healthcare IT business unit in November 2025, which significantly impacted segment performance and financial comparisons. The transaction contributed to gains recognized during the year and reflects management’s broader strategy to streamline operations and focus on higher-margin business areas.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Vaso Stock Declines Post Q4 Earnings Despite Revenue Growth
Shares of Vaso Corporation (VASO - Free Report) have lost 0.1% since the company reported its earnings for the quarter ended Dec. 31, 2025, underperforming the S&P 500 Index, which gained 3.9% over the same period. Over the past month, the stock lost 6.3% compared with a 3.5% dip in the broader index.
VASO’s Earnings Snapshot
For the fourth quarter of 2025, Vaso reported revenues of $27.02 million, essentially flat compared with $27.04 million in the year-ago quarter. Gross profit increased 2.3% year over year to $17.6 million from $17.2 million, reflecting improved margins. However, quarterly net income declined 47.4% to $1.1 million from $2.1 million in the prior-year period, primarily due to higher selling, general and administrative (SG&A) expenses and a goodwill impairment charge.
On a full-year basis, revenue rose 2.7% to $89.1 million from $86.8 million, while net income increased 64.9% to $1.6 million from $0.9 million in 2024.
Segmentally, IT revenue declined 7.9% in the quarter to $10.2 million due to the divestiture of the healthcare IT unit, while professional sales service revenue grew 6.3% to $15.9 million, driven by higher equipment deliveries and commission rates. Equipment segment revenue fell 7.6% to $851 thousand due to weaker China sales.
Vaso’s Segment Performance and Margins
The professional sales service segment remained the primary growth driver, benefiting from increased equipment deliveries and higher blended commission rates. For the full year, segment revenue rose 6.9% to $44.2 million from $41.3 million, contributing significantly to overall top-line expansion. In contrast, the IT segment saw a modest decline of 1.1% annually to $42.5 million from $42.9 million, reflecting the impact of the November 2025 divestiture of the healthcare IT business. The equipment segment continued to lag, with revenue down 1.5% for the year due to lower volumes in China, partially offset by growth in U.S.-based SaaS offerings.
Gross margin improvement supported profitability, with full-year gross profit increasing 5% to $54.7 million from $52.1 million. However, operating performance was pressured by higher costs, as SG&A expenses rose 6.6% to $52.2 million from $48.9 million, driven mainly by increased personnel and travel expenses in the sales segment.
Vaso Corporation Price, Consensus and EPS Surprise
Vaso Corporation price-consensus-eps-surprise-chart | Vaso Corporation Quote
VASO’s Cash Flow and Balance Sheet Strength
Vaso generated a strong operating cash flow of $9.3 million in 2025, up from $3.3 million in 2024, supported by higher order bookings and favorable timing of receivables. The company ended the year with $35.1 million in cash and cash equivalents, up from $26.3 million a year earlier, highlighting a solid liquidity position. Deferred revenue increased 10.6% to $38.6 million from $34.9 million, reflecting strong order activity in the professional sales service segment and providing visibility into future revenue recognition.
Vaso’s Management Commentary and Key Drivers
Management highlighted record annual revenue and emphasized sustained top-line growth alongside profitability improvements. The increase in net income for the year was attributed to higher gross profit, tax benefits and a gain on the sale of the healthcare IT business unit, partially offset by goodwill impairment and rising operating costs. VASO also noted ongoing efforts to realign its business portfolio to enhance efficiency and profitability.
Despite these positives, adjusted EBITDA turned negative $1.5 million in 2025 against a positive $1 million in 2024, indicating underlying pressure on operating earnings. The deterioration was largely linked to lower operating income and increased expenses.
Factors Influencing VASO’s Performance
Several factors shaped Vaso’s results during the period. The divestiture of the healthcare IT business reduced IT segment revenue but also contributed to gains and tax benefits. Meanwhile, higher SG&A expenses — particularly in sales and IT operations — offset gains from improved gross margins. Additionally, a goodwill impairment charge in the IT segment weighed on quarterly profitability.
Growth in the professional sales service segment was supported by strong demand for GE HealthCare equipment and improved commission structures, underscoring the importance of this segment to VASO’s overall performance.
Vaso’s Other Developments
A key development during the quarter was the sale of Vaso’s healthcare IT business unit in November 2025, which significantly impacted segment performance and financial comparisons. The transaction contributed to gains recognized during the year and reflects management’s broader strategy to streamline operations and focus on higher-margin business areas.